Synergism between a serotonin 5-HT2A receptor (5-HT 2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction

Kathryn Cunningham, Noelle Anastasio, Robert G. Fox, Sonja J. Stutz, Marcy J. Bubar, Sarah E. Swinford, Cheryl S. Watson, Scott R. Gilbertson, Kenner C. Rice, Sharon Rosenzweig-Lipson, F. Gerard Moeller

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Relapse to cocaine dependence, even after extended abstinence, involves a number of liability factors including impulsivity (predisposition toward rapid, unplanned reactions to stimuli without regard to negative consequences) and cue reactivity (sensitivity to cues associated with cocaine-taking which can promote cocaine-seeking). These factors have been mechanistically linked to serotonin (5-hydroxytryptamine, 5-HT) signaling through the 5-HT2A receptor (5-HT2AR) and 5-HT2CR; either a selective 5-HT 2AR antagonist or a 5-HT2CR agonist suppresses impulsivity and cocaine-seeking in preclinical models. We conducted proof-of-concept analyses to evaluate whether a combination of 5-HT2AR antagonist plus 5-HT2CR agonist would have synergistic effects over these liability factors for relapse as measured in a 1-choice serial reaction time task and cocaine self-administration/reinstatement assay. Combined administration of a dose of the selective 5-HT2AR antagonist M100907 plus the 5-HT 2CR agonist WAY163909, each ineffective alone, synergistically suppressed cocaine-induced hyperactivity, inherent and cocaine-evoked impulsive action, as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior. The identification of synergism between a 5-HT2AR antagonist plus a 5-HT2CR agonist to attenuate these factors important in relapse indicates the promise of a bifunctional ligand as an anti-addiction pharmacotherapeutic, setting the stage to develop new ligands with improved efficacy, potency, selectivity, and in vivo profiles over the individual molecules.

Original languageEnglish (US)
Pages (from-to)110-121
Number of pages12
JournalACS Chemical Neuroscience
Volume4
Issue number1
DOIs
StatePublished - Jan 16 2013

Fingerprint

Serotonin 5-HT2 Receptor Antagonists
Cocaine-Related Disorders
Cocaine
Receptor, Serotonin, 5-HT2A
Cues
Impulsive Behavior
Recurrence
Serotonin
Ligands
Serotonin Receptor Agonists
Self Administration
Reaction Time
Assays

Keywords

  • 1-Choice serial reaction time task
  • 5-HT receptor, 5-HT receptor
  • cocaine
  • cue reactivity
  • impulsivity, self-administration
  • serotonin

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Physiology
  • Cognitive Neuroscience

Cite this

Synergism between a serotonin 5-HT2A receptor (5-HT 2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. / Cunningham, Kathryn; Anastasio, Noelle; Fox, Robert G.; Stutz, Sonja J.; Bubar, Marcy J.; Swinford, Sarah E.; Watson, Cheryl S.; Gilbertson, Scott R.; Rice, Kenner C.; Rosenzweig-Lipson, Sharon; Moeller, F. Gerard.

In: ACS Chemical Neuroscience, Vol. 4, No. 1, 16.01.2013, p. 110-121.

Research output: Contribution to journalArticle

Cunningham, K, Anastasio, N, Fox, RG, Stutz, SJ, Bubar, MJ, Swinford, SE, Watson, CS, Gilbertson, SR, Rice, KC, Rosenzweig-Lipson, S & Moeller, FG 2013, 'Synergism between a serotonin 5-HT2A receptor (5-HT 2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction', ACS Chemical Neuroscience, vol. 4, no. 1, pp. 110-121. https://doi.org/10.1021/cn300072u
Cunningham, Kathryn ; Anastasio, Noelle ; Fox, Robert G. ; Stutz, Sonja J. ; Bubar, Marcy J. ; Swinford, Sarah E. ; Watson, Cheryl S. ; Gilbertson, Scott R. ; Rice, Kenner C. ; Rosenzweig-Lipson, Sharon ; Moeller, F. Gerard. / Synergism between a serotonin 5-HT2A receptor (5-HT 2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. In: ACS Chemical Neuroscience. 2013 ; Vol. 4, No. 1. pp. 110-121.
@article{4cdaef70279048e2ba46a1e6618b0acd,
title = "Synergism between a serotonin 5-HT2A receptor (5-HT 2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction",
abstract = "Relapse to cocaine dependence, even after extended abstinence, involves a number of liability factors including impulsivity (predisposition toward rapid, unplanned reactions to stimuli without regard to negative consequences) and cue reactivity (sensitivity to cues associated with cocaine-taking which can promote cocaine-seeking). These factors have been mechanistically linked to serotonin (5-hydroxytryptamine, 5-HT) signaling through the 5-HT2A receptor (5-HT2AR) and 5-HT2CR; either a selective 5-HT 2AR antagonist or a 5-HT2CR agonist suppresses impulsivity and cocaine-seeking in preclinical models. We conducted proof-of-concept analyses to evaluate whether a combination of 5-HT2AR antagonist plus 5-HT2CR agonist would have synergistic effects over these liability factors for relapse as measured in a 1-choice serial reaction time task and cocaine self-administration/reinstatement assay. Combined administration of a dose of the selective 5-HT2AR antagonist M100907 plus the 5-HT 2CR agonist WAY163909, each ineffective alone, synergistically suppressed cocaine-induced hyperactivity, inherent and cocaine-evoked impulsive action, as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior. The identification of synergism between a 5-HT2AR antagonist plus a 5-HT2CR agonist to attenuate these factors important in relapse indicates the promise of a bifunctional ligand as an anti-addiction pharmacotherapeutic, setting the stage to develop new ligands with improved efficacy, potency, selectivity, and in vivo profiles over the individual molecules.",
keywords = "1-Choice serial reaction time task, 5-HT receptor, 5-HT receptor, cocaine, cue reactivity, impulsivity, self-administration, serotonin",
author = "Kathryn Cunningham and Noelle Anastasio and Fox, {Robert G.} and Stutz, {Sonja J.} and Bubar, {Marcy J.} and Swinford, {Sarah E.} and Watson, {Cheryl S.} and Gilbertson, {Scott R.} and Rice, {Kenner C.} and Sharon Rosenzweig-Lipson and Moeller, {F. Gerard}",
year = "2013",
month = "1",
day = "16",
doi = "10.1021/cn300072u",
language = "English (US)",
volume = "4",
pages = "110--121",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Synergism between a serotonin 5-HT2A receptor (5-HT 2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction

AU - Cunningham, Kathryn

AU - Anastasio, Noelle

AU - Fox, Robert G.

AU - Stutz, Sonja J.

AU - Bubar, Marcy J.

AU - Swinford, Sarah E.

AU - Watson, Cheryl S.

AU - Gilbertson, Scott R.

AU - Rice, Kenner C.

AU - Rosenzweig-Lipson, Sharon

AU - Moeller, F. Gerard

PY - 2013/1/16

Y1 - 2013/1/16

N2 - Relapse to cocaine dependence, even after extended abstinence, involves a number of liability factors including impulsivity (predisposition toward rapid, unplanned reactions to stimuli without regard to negative consequences) and cue reactivity (sensitivity to cues associated with cocaine-taking which can promote cocaine-seeking). These factors have been mechanistically linked to serotonin (5-hydroxytryptamine, 5-HT) signaling through the 5-HT2A receptor (5-HT2AR) and 5-HT2CR; either a selective 5-HT 2AR antagonist or a 5-HT2CR agonist suppresses impulsivity and cocaine-seeking in preclinical models. We conducted proof-of-concept analyses to evaluate whether a combination of 5-HT2AR antagonist plus 5-HT2CR agonist would have synergistic effects over these liability factors for relapse as measured in a 1-choice serial reaction time task and cocaine self-administration/reinstatement assay. Combined administration of a dose of the selective 5-HT2AR antagonist M100907 plus the 5-HT 2CR agonist WAY163909, each ineffective alone, synergistically suppressed cocaine-induced hyperactivity, inherent and cocaine-evoked impulsive action, as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior. The identification of synergism between a 5-HT2AR antagonist plus a 5-HT2CR agonist to attenuate these factors important in relapse indicates the promise of a bifunctional ligand as an anti-addiction pharmacotherapeutic, setting the stage to develop new ligands with improved efficacy, potency, selectivity, and in vivo profiles over the individual molecules.

AB - Relapse to cocaine dependence, even after extended abstinence, involves a number of liability factors including impulsivity (predisposition toward rapid, unplanned reactions to stimuli without regard to negative consequences) and cue reactivity (sensitivity to cues associated with cocaine-taking which can promote cocaine-seeking). These factors have been mechanistically linked to serotonin (5-hydroxytryptamine, 5-HT) signaling through the 5-HT2A receptor (5-HT2AR) and 5-HT2CR; either a selective 5-HT 2AR antagonist or a 5-HT2CR agonist suppresses impulsivity and cocaine-seeking in preclinical models. We conducted proof-of-concept analyses to evaluate whether a combination of 5-HT2AR antagonist plus 5-HT2CR agonist would have synergistic effects over these liability factors for relapse as measured in a 1-choice serial reaction time task and cocaine self-administration/reinstatement assay. Combined administration of a dose of the selective 5-HT2AR antagonist M100907 plus the 5-HT 2CR agonist WAY163909, each ineffective alone, synergistically suppressed cocaine-induced hyperactivity, inherent and cocaine-evoked impulsive action, as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior. The identification of synergism between a 5-HT2AR antagonist plus a 5-HT2CR agonist to attenuate these factors important in relapse indicates the promise of a bifunctional ligand as an anti-addiction pharmacotherapeutic, setting the stage to develop new ligands with improved efficacy, potency, selectivity, and in vivo profiles over the individual molecules.

KW - 1-Choice serial reaction time task

KW - 5-HT receptor, 5-HT receptor

KW - cocaine

KW - cue reactivity

KW - impulsivity, self-administration

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=84866370991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866370991&partnerID=8YFLogxK

U2 - 10.1021/cn300072u

DO - 10.1021/cn300072u

M3 - Article

C2 - 23336050

AN - SCOPUS:84866370991

VL - 4

SP - 110

EP - 121

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

ER -